Fig. 1From: Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe diseaseSARS‐CoV‐2 infection induced inflammatory response and “bi-anti” therapyBack to article page